Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Roche Holding AG (RO)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
373.00 -1.00    -0.27%
11:31:00 - Closed. Currency in CHF ( Disclaimer )
Type:  Equity
Market:  Switzerland
ISIN:  CH0012032113 
VALOR:  1203211
  • Volume: 55,340
  • Bid/Ask: 373.00 / 373.80
  • Day's Range: 368.60 - 375.00
Roche Holding 373.00 -1.00 -0.27%
Period Ending: 2020
31/12
2020
30/06
2019
31/12
2019
30/06
Total Current Assets 32942 27703 31254 32315
Cash and Short Term Investments 12334 6252 11858 11172
Cash - - - -
Cash & Equivalents 5727 3770 6075 5689
Short Term Investments 6607 2482 5783 5483
Total Receivables, Net 10303 11855 10677 11951
Accounts Receivables - Trade, Net 10154 11666 10440 11760
Total Inventory 7194 6787 6055 6574
Prepaid Expenses - - - -
Other Current Assets, Total 3111 2809 2664 2618
Total Assets 86138 80363 83091 80194
Property/Plant/Equipment, Total - Net 23270 23247 23318 23163
Property/Plant/Equipment, Total - Gross - - - -
Accumulated Depreciation, Total - - - -
Goodwill, Net 9249 10109 12456 8878
Intangibles, Net 12017 11394 8358 9078
Long Term Investments - - - -
Note Receivable - Long Term - - - -
Other Long Term Assets, Total 8660 7910 7705 6760
Other Assets, Total - - - -
Total Current Liabilities 25401 22463 24119 23446
Accounts Payable 4121 3042 3822 3250
Payable/Accrued - - - -
Accrued Expenses - - - -
Notes Payable/Short Term Debt 2189 2551 1694 1637
Current Port. of LT Debt/Capital Leases 1807 1 1 2536
Other Current liabilities, Total 17284 16869 18602 16023
Total Liabilities 49797 48854 50344 52135
Total Long Term Debt 10220 12491 12668 15398
Long Term Debt 10220 12491 12668 15398
Capital Lease Obligations - - - -
Deferred Income Tax 353 301 298 246
Minority Interest 3432 3306 3120 2957
Other Liabilities, Total 10391 10293 10139 10088
Total Equity 36341 31509 32747 28059
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 160 160 160 160
Additional Paid-In Capital - - - -
Retained Earnings (Accumulated Deficit) 45571 39816 40524 35527
Treasury Stock - Common - - - -
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) 106 89 15 34
Other Equity, Total -9496 -8556 -7952 -7662
Total Liabilities & Shareholders' Equity 86138 80363 83091 80194
Total Common Shares Outstanding 853.13 854.64 855.76 856.06
Total Preferred Shares Outstanding - - - -
* In Millions of CHF (except for per share items)
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

RO Comments

Write your thoughts about Roche Holding AG
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Sherlyn Jones
Sherlyn Jones Apr 22, 2021 6:47AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
A large pharmaceutical company, by the name of R. , is pushing down the value of the Spanish company's Pharmamar share price through the funds Consonance Capital and Great Point Partners, so that the biotech company accepts its offer of more than 4500 million dollars.According to this pharma, Pharmamar's products have a great future in oncology and virology, and would be fully engaged in its search for new drugs.
Ruta Rublevska
Ruta Rublevska Nov 16, 2020 3:37AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
13.11.2020. CHMP recommends EU approval of Roche’s Xofluza® (baloxavir marboxil) for the treatment of influenza. This CHMP recommendation brings patients with influenza one step closer to potentially benefiting from Xofluza’s oral one-dose regimen, setting adults and adolescents on the path to feeling better sooner compared to placebo,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We believe that access to effective antivirals for influenza, and particularly their use in the prophylactic setting, could help reduce the strain of the COVID-19 pandemic on healthcare systems in Europe.
Jonny Tr
Jonny Tr May 04, 2020 8:36AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Just like Biolidics. they get approval for Covid19 tests kits in USA
Billy Hanafi
Billy Hanafi Jan 25, 2019 10:12AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
i dont know
edgard hajjar
edgard hajjar May 07, 2018 5:38PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
is the historical price adjusted for stock splits?
Billy Hanafi
Billy Hanafi May 07, 2018 5:38PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
i dont know
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email